Ovid Therapeutics (OVID) Accumulated Expenses (2016 - 2026)

Ovid Therapeutics' Accumulated Expenses history runs 11 years deep, the most recent figure standing at $5.4 million for Q1 2026.

• Quarterly Accumulated Expenses fell 9.74% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (down 9.74% YoY) and the FY2025 annual result came in at $4.9 million, down 18.27% from the prior year.
• Accumulated Expenses was $5.4 million for Q1 2026 at Ovid Therapeutics, up from $4.9 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $8.1 million in Q2 2024 and bottomed at $2.9 million in Q2 2025.
• A 5-year average of $5.5 million and a median of $5.4 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 567.03% — and 2025, when it slumped 64.58%.
• Ovid Therapeutics' Accumulated Expenses stood at $4.5 million in 2022, then soared by 44.83% to $6.5 million in 2023, then slipped by 8.12% to $6.0 million in 2024, then declined by 18.27% to $4.9 million in 2025, then gained by 10.49% to $5.4 million in 2026.
• Business Quant data shows OVID's Accumulated Expenses at $5.4 million in Q1 2026, $4.9 million in Q4 2025, and $3.0 million in Q3 2025.